TG
TPG GP A, LLC
13F filer · CIK 0001903793Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$5BU.S. long equity reported on 13F
Positions5111 new · 7 closed
Net flow last quarter+$260MBuys minus sells
Top 10 positions weight76.3%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202651 positions | |||||
| $1.2B | 23.93% | 29.25% | -20.2% | Q4 2021 | |
| $735M | 14.69% | Not reported | New | Q2 2026 | |
| $483M | 9.65% | 6.92% | Not reported | Q1 2026 | |
| $322M | 6.45% | 3.54% | -55.7% | Q4 2021 | |
| $286M | 5.71% | 14.38% | Not reported | Q1 2025 | |
| $275M | 5.49% | 43.63% | Not reported | Q4 2025 | |
| $213M | 4.27% | 3.86% | Not reported | Q4 2021 | |
| $124M | 2.48% | 0.70% | New | Q2 2026 | |
| $92.1M | 1.84% | 4.63% | -2.5% | Q1 2026 | |
| BTBCAXBicara Therapeutics Inc. | $89.4M | 1.79% | 4.57% | Not reported | Q3 2024 |
| $78.3M | 1.56% | Not reported | +7.7% | Q1 2026 | |
| $73.2M | 1.46% | 9.84% | -5.2% | Q4 2024 | |
| $69M | 1.38% | 7.71% | New | Q2 2026 | |
| $44.9M | 0.90% | 6.70% | New | Q2 2026 | |
| $41.7M | 0.83% | Not reported | -7.6% | Q1 2026 | |
| $38.9M | 0.78% | 5.42% | Not reported | Q4 2021 | |
| $38.3M | 0.76% | 4.47% | Not reported | Q1 2026 | |
| $25.6M | 0.51% | 4.14% | -67.8% | Q1 2026 | |
| $25.4M | 0.51% | 1.74% | New | Q2 2026 | |
| $20.5M | 0.41% | Not reported | +13.5% | Q1 2026 | |
| $20M | 0.40% | 3.11% | Not reported | Q4 2021 | |
| $19.2M | 0.38% | Not reported | +66.7% | Q1 2026 | |
| $15.3M | 0.31% | Not reported | New | Q2 2026 | |
| EAEAElectronic Arts Inc. | $13.3M | 0.27% | Not reported | Not reported | Q1 2026 |
| $12.6M | 0.25% | 0.02% | Not reported | Q1 2026 | |
| CIGTLSChart Industries Inc | $10.4M | 0.21% | 0.10% | +66.7% | Q1 2026 |
| $7.64M | 0.15% | 0.02% | +33.3% | Q1 2026 | |
| $6.32M | 0.13% | 0.05% | Not reported | Q1 2026 | |
| $6.06M | 0.12% | 7.13% | Not reported | Q4 2021 | |
| $5.6M | 0.11% | 0.01% | -28.8% | Q1 2026 | |
| $5.13M | 0.10% | 0.18% | +62.5% | Q1 2026 | |
| NNUVLNuvalent, Inc. | $4.94M | 0.10% | 1.28% | New | Q2 2026 |
| ATAPGEApogee Therapeutics, Inc. | $3.32M | 0.07% | 0.03% | New | Q2 2026 |
| TBLDTopBuild Corp | $2.91M | 0.06% | 0.02% | New | Q2 2026 |
| $2.28M | 0.05% | 0.91% | Not reported | Q1 2026 | |
| $2.2M | 0.04% | 0.02% | New | Q2 2026 | |
| $2.12M | 0.04% | 0.02% | New | Q2 2026 | |
| $1.7M | 0.03% | 1.99% | +32.0% | Q1 2026 | |
| $478K | 0.01% | 0.02% | Not reported | Q1 2026 | |
| $65.3K | 0.00% | Not reported | Not reported | Q1 2026 | |
| $41.6K | 0.00% | Not reported | Not reported | Q1 2026 | |
| $37K | 0.00% | Not reported | Not reported | Q1 2026 | |
| $15.1K | 0.00% | Not reported | Not reported | Q1 2026 | |
| $6.9K | 0.00% | Not reported | Not reported | Q1 2026 | |
| $4.94K | 0.00% | Not reported | Not reported | Q1 2026 | |
| $3.44K | 0.00% | Not reported | Not reported | Q1 2026 | |
| $3.18K | 0.00% | Not reported | Not reported | Q1 2026 | |
| $2.02K | 0.00% | Not reported | Not reported | Q1 2026 | |
| $1.45K | 0.00% | Not reported | Not reported | Q1 2026 | |
| $1.15K | 0.00% | Not reported | Not reported | Q1 2026 | |
| Q1 2026Reported May 15, 202647 positions | |||||
| $892M | 24.25% | 36.11% | -12.9% | Q4 2021 | |
| $499M | 13.55% | 6.71% | New | Q1 2026 | |
| $480M | 13.06% | 8.02% | Not reported | Q4 2021 | |
| $260M | 7.08% | 14.41% | -3.7% | Q1 2025 | |
| $241M | 6.55% | 43.63% | Not reported | Q4 2025 | |
| $153M | 4.17% | 3.92% | Not reported | Q4 2021 | |
| $73.2M | 1.99% | 4.79% | New | Q1 2026 | |
| $72.7M | 1.98% | 10.48% | Not reported | Q4 2024 | |
| $70.9M | 1.93% | Not reported | New | Q1 2026 | |
| BTBCAXBicara Therapeutics Inc. | $59.9M | 1.63% | 4.59% | Not reported | Q3 2024 |
| $47M | 1.28% | Not reported | New | Q1 2026 | |
| $45.7M | 1.24% | 7.65% | Not reported | Q4 2021 | |
| $36.9M | 1.00% | 4.47% | New | Q1 2026 | |
| $35.4M | 0.96% | Not reported | New | Q1 2026 | |
| $18.9M | 0.51% | Not reported | New | Q1 2026 | |
| $18.7M | 0.51% | 3.08% | Not reported | Q4 2021 | |
| EAEAElectronic Arts Inc. | $13.3M | 0.36% | Not reported | New | Q1 2026 |
| $11.5M | 0.31% | 0.02% | New | Q1 2026 | |
| CACWANClearwater Analytics Holdings, Inc. | $9.11M | 0.25% | Not reported | New | Q1 2026 |
| $8.55M | 0.23% | Not reported | New | Q1 2026 | |
| $8.1M | 0.22% | 0.01% | New | Q1 2026 | |
| $6.57M | 0.18% | 0.05% | New | Q1 2026 | |
| CIGTLSChart Industries Inc | $6.2M | 0.17% | 0.06% | New | Q1 2026 |
| $5.17M | 0.14% | 0.02% | New | Q1 2026 | |
| MMASIMasimo Corp | $4.45M | 0.12% | 0.05% | New | Q1 2026 |
| $3.4M | 0.09% | 7.16% | 0.0% | Q4 2021 | |
| $3.12M | 0.08% | 0.05% | New | Q1 2026 | |
| $3.08M | 0.08% | 0.11% | New | Q1 2026 | |
| $2.11M | 0.06% | 0.91% | New | Q1 2026 | |
| APAPLSApellis Pharmaceuticals, Inc. | $2.01M | 0.05% | 0.04% | New | Q1 2026 |
| $1.39M | 0.04% | 1.52% | New | Q1 2026 | |
| $324K | 0.01% | 0.02% | New | Q1 2026 | |
| $243K | 0.01% | 0.00% | New | Q1 2026 | |
| $150K | 0.00% | 0.00% | New | Q1 2026 | |
| $54K | 0.00% | Not reported | New | Q1 2026 | |
| $47.3K | 0.00% | Not reported | New | Q1 2026 | |
| $42K | 0.00% | Not reported | New | Q1 2026 | |
| $26.4K | 0.00% | Not reported | New | Q1 2026 | |
| $6.62K | 0.00% | Not reported | New | Q1 2026 | |
| $6.25K | 0.00% | Not reported | New | Q1 2026 | |
| $5.1K | 0.00% | Not reported | New | Q1 2026 | |
| $4K | 0.00% | Not reported | New | Q1 2026 | |
| $2.8K | 0.00% | Not reported | New | Q1 2026 | |
| $1.4K | 0.00% | Not reported | New | Q1 2026 | |
| $1.02K | 0.00% | Not reported | New | Q1 2026 | |
| $220 | 0.00% | Not reported | New | Q1 2026 | |
| $98 | 0.00% | Not reported | New | Q1 2026 | |
| Q4 2025Reported Feb 13, 202610 positions | |||||
| $1.13B | 42.11% | 41.39% | Not reported | Q4 2021 | |
| $474M | 17.64% | 8.07% | Not reported | Q4 2021 | |
| $463M | 17.22% | 43.63% | New | Q4 2025 | |
| $277M | 10.33% | 15.08% | Not reported | Q1 2025 | |
| $155M | 5.78% | 3.92% | Not reported | Q4 2021 | |
| $87M | 3.24% | 10.58% | Not reported | Q4 2024 | |
| BTBCAXBicara Therapeutics Inc. | $50.7M | 1.89% | 5.32% | Not reported | Q3 2024 |
| $25.6M | 0.95% | 8.16% | Not reported | Q4 2021 | |
| $20.6M | 0.77% | 3.06% | Not reported | Q4 2021 | |
| $2.09M | 0.08% | 57.32% | Not reported | Q4 2021 | |
| Q3 2025Reported Nov 14, 20259 positions | |||||
| $884M | 48.14% | 41.31% | Not reported | Q4 2021 | |
| $492M | 26.80% | 8.10% | -16.7% | Q4 2021 | |
| $198M | 10.80% | 15.17% | Not reported | Q1 2025 | |
| $123M | 6.72% | 3.93% | Not reported | Q4 2021 | |
| BTBCAXBicara Therapeutics Inc. | $47.5M | 2.59% | 5.51% | Not reported | Q3 2024 |
| $45.6M | 2.48% | 10.71% | Not reported | Q4 2024 | |
| $23.2M | 1.26% | 8.39% | Not reported | Q4 2021 | |
| $20.5M | 1.12% | 3.06% | -66.2% | Q4 2021 | |
| $1.51M | 0.08% | 7.22% | Not reported | Q4 2021 | |
Premium opens every quarter this fund has filed